Breast Cancer Clinical Trial
Official title:
Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study
The goal of this clinical research study is to learn if metformin can help to control nerve
damage (loss of motor or sensory function) that may be caused by treatment with paclitaxel
in patients with breast cancer.
In this study, metformin will be compared to a placebo. A placebo is not a drug. It looks
like the study drug, but it is not designed to treat any disease or illness. It is designed
to be compared with a study drug to learn if the study drug has any real effect.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in a roll of dice) to 1 of 2 groups. This is done because no one knows if one study
group is better, the same, or worse than the other group. You will have a 1 out of 3 chance
of being in Group 1 and a 2 out of 3 chance of being in Group 2.
- If you are in Group 1, you will take placebo pills.
- If you are in Group 2, you will take metformin pills.
Neither you nor the study staff will know if you are receiving the study drug or the
placebo. However, if needed for your safety, the study staff will be able to find out what
you are receiving.
Study Drug Administration:
You should take the pills 2 times a day at about the same time every day, preferably with
food (for example, with breakfast and dinner).
You will start taking the pills about 12 days before your paclitaxel treatment starts. This
is called the "adaptation period." It is meant to allow your body to get used to the study
pills. The study staff will check you for allergic reactions or other negative reactions to
the pills during this period. If you are not tolerating the pills, you will be taken off
study.
About every 3 weeks while you are receiving paclitaxel, you should bring the study
drug/placebo container (along with any leftover pills) to the clinic. The study staff will
count the number of pills you have taken.
Study Visits:
Every week during the study, either during your clinic visit or by phone, the study staff
will ask you about any side effects you may be having, if you have taken the study
drug/placebo, and how many pills you have taken so far. The calls should take about 10-15
minutes.
About 2 weeks before you start paclitaxel:
- You will complete questionnaires about numbness and other symptoms. It should take
about 15 minutes to complete these questionnaires.
- You will complete 3 sensory and fine-motor tests. These tests will show researchers how
sensitive you are to touching things such as small bumps and how well you are able to
pick up small objects. It should take about 15 minutes to complete these tests.
- If possible, blood (about 8 teaspoons) will also be drawn to test for markers of
inflammation. Markers of inflammation are biomarkers found in the blood and may be
related to the symptoms you have. These blood samples during the study will only be
collected if they can be drawn during a routine blood draw you are already having.
At 1-2 days before you start paclitaxel:
- You will complete the questionnaires about numbness and other symptoms.
- You will complete the sensory and fine-motor tests.
- Blood (about 8 teaspoons) will be drawn to test for markers of inflammation, if a
routine blood sample is also being drawn on that day.
Every week while you are receiving paclitaxel, you will complete a questionnaire in the
clinic or by phone about any symptoms you may be having, and how the symptoms may be
affecting your daily activities. This questionnaire should take about 5 minutes to complete.
About every 3 weeks while you are receiving paclitaxel, at your clinic visits:
- You will complete the questionnaires about numbness.
- You will also complete the sensory and fine-motor dexterity tests.
At about Weeks 6 and 12 while you are receiving paclitaxel, at your clinic visits, blood
(about 8 teaspoons) will be drawn to test for markers of inflammation, if a routine blood
sample is also being drawn on that day.
At about Week 12 while you are receiving paclitaxel, at your clinic visit, you will complete
a questionnaire about how satisfied you are with the study drug/placebo. Completing the
questionnaire should take about 5 minutes.
Length of Study:
You may take the study drug/placebo for up to 12 weeks. You will no longer be able to take
the study drug/placebo if the disease gets worse, if intolerable side effects occur, or if
you are unable to follow study directions.
Your participation in the study will be over after the end-of-study visit.
End-of-Study Visit:
About 4 weeks after you finish receiving the study drug/placebo:
- You will complete the questionnaires about numbness and other symptoms.
- You will complete the sensory and fine-motor tests.
- Blood (about 8 teaspoons) will be drawn to test for markers of inflammation, if a
routine blood sample is also being drawn on that day.
This is an investigational study. Metformin is FDA approved and commercially available for
the treatment of a type of diabetes. Its use in this study is investigational. The study
doctor can explain how the study drug is designed to work.
Up to 42 participants will be enrolled in this study. All will take part at the Harris
Health System.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |